Navigation Links
Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting

MAPLE GROVE, Minn., Nov. 5, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that seven abstracts highlighting results from its Phase 3 (PREVAIL) clinical trial for USL255 (extended-release topiramate) have been accepted for presentation at the American Epilepsy Society's (AES) 67th Annual Meeting in Washington, DC, December 6-10, 2013.


USL255 is a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic profile.  It is being developed by Upsher-Smith for the management of epilepsy.  Upsher-Smith's New Drug Application for USL255 has been accepted for review by the U.S. Food and Drug Administration (FDA).

PREVAIL, a global Phase 3 study, enrolled more than 200 patients at 66 centers to evaluate the safety and efficacy of USL255.  USL255 demonstrated a positive treatment effect as adjunctive therapy in patients with refractory partial-onset seizures (POS) compared with placebo and had a statistically significant reduction from baseline in weekly POS frequency during the titration plus maintenance phase compared to placebo (p<0.001). 

"Upsher-Smith is committed to researching and developing potential treatment options for patients living with challenging central nervous system diseases like seizure disorders," said William Pullman, MB BS, BMedSc, PhD, FRACP, Chief Scientific Officer, Upsher-Smith.  "We look forward to sharing the data from our global Phase 3 clinical trial, the first of its kind conducted on an extended-release formulation of topiramate, with the epilepsy community at this year's AES meeting."

About Upsher-Smith's Phase 3 (PREVAIL) Clinical Trial
The PREVAIL trial was a randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of USL255 as adjunctive therapy in patients with refractory POS. 

PREVAIL was conducted under a Special Protocol Assessment (SPA) agreement with the FDA.  More information about the trial is available at (NCT01142193).

An open-label extension study to evaluate the safety of USL255 as adjunctive therapy in patients with refractory POS who had participated in PREVAIL is ongoing.  The open-label extension study can be found by searching NCT01191086 on

Upsher-Smith's Epilepsy Pipeline
Upsher-Smith's clinical development pipeline includes three investigational drugs that are being studied for the management of seizure disorders.  USL255 is an investigational once-daily, extended-release topiramate for the management of epilepsy.  The pipeline also includes USL261, an investigational intranasal midazolam for the rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters, which is the subject of an ongoing international Phase 3 clinical trial (ARTEMIS1) with an open-label safety extension study.  In addition, USL260 (tonabersat) is in early clinical development as a potential first-in-class neuronal gap junction modulator.

About Upsher-Smith
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded and generic pharmaceuticals.  Upsher-Smith has a particular focus on developing therapies to assist people suffering from central nervous system diseases and also markets products relating to cardiology, dermatology, and women's health.  For more information, visit

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Announces Development Agreement With Lundbeck
2. Upsher-Smith Announces Commercial Availability Of Morphine Sulfate ER Capsules
3. Upsher-Smith Teams Up With Epilepsy Foundation Of Minnesota For 2013 Stroll For Epilepsy
4. Upsher-Smith Announces Patient Enrollment In Open-label Safety Study Of USL261 (Intranasal Midazolam) For Rescue Treatment Of Seizure Clusters In Epilepsy
5. Upsher-Smith Is Honored With Prestigious Industry Award For Leadership And Innovation
6. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
7. Upsher-Smith Introduces Newly Redesigned Corporate Website
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
10. Doug Zitnak of Upsher-Smith Laboratories Named Small Brand Manufacturer Representative of the Year By Cardinal Health
11. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
Post Your Comments:
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... , Nov. 25, 2015 On ... first federal bellwether trial against Wright Medical Technology, ... to their Conserve metal-on-metal hip implant device, awarded ... Following a two week trial and three days ... metal-on-metal hip device was defectively designed and unreasonably ...
Breaking Medicine Technology:
(Date:11/26/2015)... BOSTON, Mass. (PRWEB) , ... November 26, 2015 ... ... a thorough second medical opinion process, participated in the 61st annual Employee Benefits ... Benefit Plans and took place Sunday, November 8th through Wednesday, November 11th, 2015. ...
(Date:11/25/2015)... ... 2015 , ... As part of a global movement to ... together who want to combine talents and resources to help create sustainable communities ... The non-profit launched its first major fundraiser on November 6, 2015 at Bent ...
(Date:11/25/2015)... NV (PRWEB) , ... November 25, 2015 , ... Dr. ... patients to learn more about hair loss treatment with the Capillus272™ Pro laser therapy ... effective solution for thicker and fuller hair, without the need for surgery, prescription pills, ...
(Date:11/25/2015)... ... 25, 2015 , ... Lakeview Health, a Jacksonville-based drug and ... sobriety and show through pictures what a positive difference it makes. The social ... the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories ...
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
Breaking Medicine News(10 mins):